People with Eating Disorders Are Being Prescribed Weight Loss Medication More Often

<>

Text
A growing number of individuals with eating disorders in Sweden are being prescribed weight-loss medications, according to recent reports from Sveriges Radio and Metro. The trend, highlighted in a June 2026 analysis, has sparked debate among healthcare professionals and patients about the appropriateness and long-term implications of such treatments.

The findings, based on data from Sweden’s National Board of Health and Welfare, show that prescriptions for weight-loss medications among patients with diagnosed eating disorders increased significantly between 2023 and 2025. This rise contrasts with broader trends in obesity treatment, where such medications are typically reserved for individuals without concurrent mental health conditions.

The reports cite interviews with patients, including Carina, a 28-year-old from Stockholm who has struggled with bulimia for over a decade. “The injection is not the solution,” Carina said. “It helps with weight, but it doesn’t fix the cycle of bingeing and guilt. I feel like I’m just managing symptoms, not healing.”

Sveriges Radio’s investigation also revealed that some healthcare providers are using weight-loss medications as a short-term intervention to stabilize patients’ physical health before addressing psychological triggers. However, this approach is not universally supported. The Swedish Association for Eating Disorders (SAED) issued a statement cautioning against “overreliance on pharmacological solutions without concurrent therapeutic support.”

The data underscores a broader tension in modern medicine: the pressure to address obesity while navigating the complexities of mental health. In 2025, the World Health Organization (WHO) updated its guidelines to emphasize holistic care for patients with comorbid conditions, but implementation varies widely.

While the Swedish National Board of Health and Welfare has not issued formal guidance on the matter, the reports have prompted calls for updated clinical protocols. A draft proposal from the National Board, leaked to Metro in June 2026, suggests that weight-loss medications should be prescribed only under strict supervision and in conjunction with psychotherapy.

The debate reflects broader challenges in healthcare policy, particularly in balancing innovation with patient safety. As new weight-loss drugs continue to enter the market, the focus remains on ensuring their use aligns with the unique needs of individuals with eating disorders.

Text
Subheading
Why the Trend?

The increase in weight-loss medication prescriptions for eating disorder patients coincides with the approval of newer drugs, such as semaglutide and liraglutide, which have shown efficacy in managing weight and appetite. These medications, originally developed for diabetes, have gained popularity for off-label use in weight management.

However, their application in eating disorder treatment remains controversial. A 2024 study published in the Journal of Clinical Endocrinology & Metabolism